A product review of vedolizumab in inflammatory bowel disease

• Asıl Yazarlar: Robert Battat (Yazar), Parambir S. Dulai (Yazar), Vipul Jairath (Yazar), Niels Vande Casteele (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Taylor & Francis Group, 2019-10-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Vedolizumab is a monoclonal antibody to the α4β7 integrin that selectively reduces intestinal lymphocyte trafficking, thereby providing a safe and effective treatment option for patients with inflammatory bowel disease (IBD). This product review outlines the unique mechanism of vedolizumab in additi...